ABSTRACT: The JumpStart service provides CDER Review Teams with an assessment of the composition and quality of the clinical trial data submitted within an application. From inception, the JumpStart service has provided an assessment of 66 applications. Through this analysis, the service has tracked common issues that impact review. JumpStart has also identified additional data-related items that could assist review, if implemented. JumpStart has developed suggestions based on this tracking and identification process.

Data Quality Findings from JumpStart

DeYett Law1, Crystal Allard1, Eileen Navarro1, Mary Doi1, Timothy Kropp1, Lilliam Rosario1, Dave Epstein2, Kathryn Matto3, Austin Taylor3, Jeno Pizarro3, Margo Cohen3
1 Office of Computational Science, 2 Chickasaw, 3 IBM

Study Data Reviewer's Guide (SDRG)
- not provided or missing key sections
  - 38%
- EPOCH variable not provided for all events, interventions, and findings domains
  - 75%
- Adverse event seriousness criteria missing for adverse events designated as serious
  - 46%
- Trial summary domain not provided in the study data package
  - 8%

JumpStart has analyzed 66 applications since FY13

Data Package Suggestions from JumpStart Findings

Define File
- Use Define.xml v2.0
- Include detailed description of data elements, for example:
  - Code lists that describe categories, subcategories, and reference time-points
  - Detailed and reproducible computational algorithms for all derived variables
  - Applicable value level metadata and description of SUPPQUAL domains
  - Explanations of sponsor-defined identifiers (i.e. – SPID, GRPID, etc)
- Provide separate unit code lists for each domain

Study Data Reviewer’s Guide (SDRG)
- Provide SDRG for each data package with each section populated
- Fix all possible issues identified by FDA Validation Rules and include clear and detailed explanation for all “non-fixable” issues
- Provide Data Flow diagram that shows traceability between data capture, storage, and creation of datasets

Disposition Domain Suggestions
- Include time-point information (event start/end date) for the even in Disposition records, not just when the event was recorded
- Include records regarding subject study completion and last follow-up contact with subject in disposition domain
- Accurately code reasons why subject did not complete the study or study treatment

Generic Data Suggestions
- Harmonize MedDRA versions across studies within an application
- Ensure consistent subject death information across all datasets and records
- Remove duplicate records
- Use the most recent version of FDA Validation Rules and fix data issues identified
- Populate RFPENDTC according to SDTM guidance
- Properly use ACTARM variable
- Include study day variable (--DY (Study Day), -- STDY (Study Day of Start of Observation), -- ENDY (Study day of end of observation)) for all observational datasets
- Use CDISC controlled terminology variables when available
- Provide EPOCH variable in all appropriate domains
- Use Baseline flags in LB and VS domains
- Provide AE Treatment Emergent Flag within the SUPPAE domain
- Include Seriousness Criteria for all Serious Adverse Events
- Provide Trial Design domains that are complete and accurate